文献速递乳腺介入US乳腺X线

不接受手术的早期乳腺癌患者对冷冻消融治疗的接受度及结果

Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients.
PubMed 文献 · Br J Radiol · 2024-01-01

回顾性分析本机构2020年1月至2023年12月诊断的63例拒绝手术的早期乳腺癌患者(66个病灶),其中45例被提供经皮冷冻消融(PCA),43例(95.6%)接受。39个恶性肿瘤(中位大小24mm)接受超声引导下PCA,随访≥6个月者完全肿瘤坏死率81.3%,中位随访16个月时≤25mm的Luminal型乳腺癌完全消融率100%,无重大并发症。作者认为PCA安全、有效、耐受良好,可能成为该组患者手术的替代选择。

要点

  • 拒绝手术的早期乳腺癌患者中,被提供PCA者接受率高达95.6%(43/45)。
  • 随访≥6个月者完全肿瘤坏死率为81.3%,≤25mm的Luminal型乳腺癌完全消融率达100%。
  • PCA为超声引导下门诊手术,无重大并发症,患者耐受良好。

核心结论

  • 不接受手术的早期乳腺癌患者接受PCA治疗;PCA是安全、有效且耐受良好的门诊手术,研究结果提示PCA可能成为该组患者手术的替代选择。

研究设计与样本

  • 回顾性分析本机构2020年1月至2023年12月经活检证实的早期乳腺癌非手术患者,共63例患者66个早期乳腺癌病灶;PCA在超声引导下使用液氮系统进行;术后每6个月进行乳腺X线摄影和超声或对比增强乳腺X线摄影随访,持续5年。

诊断标准与关键数值

  • 45例被提供PCA的患者中43例(95.6%)接受;39个恶性肿瘤(中位大小24mm)接受PCA,所有病例均经多学科肿瘤委员会事先审查;随访≥6个月者完全肿瘤坏死率为81.3%;中位随访16个月时,≤25mm的Luminal型乳腺癌完全消融率为100%。

临床应用与阅片要点

  • 作者认为PCA可能成为该组拒绝手术的早期乳腺癌患者手术的替代选择,尤其对≤25mm的Luminal型肿瘤可能实现局部控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Evaluate acceptance of percutaneous cryoablation (PCA) treatment by patients with early breast cancer (BC) who choose not to have surgery and present our experience in the use of PCA for the local control of BC in this group of patients.

METHODS: All biopsy-proven early BC diagnosed in our institution as non-surgical patients between January 2020 and December 2023 were retrospectively reviewed. We recorded if PCA was offered and if it was accepted by the patient. PCA was performed under ultrasound (US) guidance, using a liquid nitrogen-based system. Mammography and US or contrast-enhanced mammography follow-up was scheduled every 6 months for 5 years. Patient's tolerance to the procedure, adverse effects, and results regarding local control of the disease were assessed.

RESULTS: A total of 66 early BC were diagnosed in 63 patients who decided not to have surgery. Median age was 88 years (range 60-99 years). Forty-three (95.6%) of the 45 patients offered PCA accepted. Thirty-nine malignant tumours (median size 24 mm) underwent PCA. All cases were previously reviewed in a multidisciplinary tumour board. Complete tumour necrosis was achieved in 81.3% of the cases followed for ≥ 6 months. After a median follow-up of 16 months, the complete ablation rate in Luminal BC ≤ 25 mm was 100%. No major complications were seen.

CONCLUSIONS: Non-surgical patients with early BC accepted PCA when the treatment was offered. PCA is safe, effective, and well-tolerated outpatient procedure. The study outcomes suggest that PCA could be an alternative to surgery for the management of BC in this group of patients.

ADVANCES IN KNOWLEDGE: Patients with early BC who choose not to have surgery accept PCA. This percutaneous approach probably allows local control of early BC, mainly in ≤25 mm Luminal tumours.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Graña-López LL, Abelairas-López LL, Fernández-Sobrado II, et al. Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients. Br J Radiol. 2024. PMID: 39073890. doi:10.1093/bjr/tqae131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。